BioCentury
DATA GRAPHICS | Product Development

Data Bytes: Cellectis remains active in allogeneic pipeline for multiple myeloma despite clinical hold

July 10, 2020 10:25 PM UTC

Even with the clinical hold on its Phase I trial of UCARTCS1A, Cellectis remains one of the most active companies developing allogeneic cell therapies for multiple myeloma, with another program -- ALLO-715 -- in Phase I testing and preclinical candidate ALLO-605 coming up behind.

Cellectis S.A. (NASDAQ:CLLS; Euronext:ALCLS) is working on ALLO-715 and ALLO-605 through its 2018 partnership with Allogene Therapeutics Inc. (NASDAQ:ALLO), which assumed rights under a previous agreement with Pfizer Inc. (NYSE:PFE). Both ALLO-605 and ALLO-715 target BCMA, the most popular target in the allogeneic pipeline for multiple myeloma...